The COVID19 episode exposed a critical weakness — the American supply chain (particularly medical and pharmaceutical manufacturing) was grounded so thoroughly in China that it could not serve the United States when it was desperately needed.
China prevented American companies from shipping product manufactured by American companies in China to the US.
Everyone was quick to say — “Bring the strategic supply chain back home to America!”
Like a lot of good ideas, it requires real action to make real change. How could this obvious strategic move be instigated? Where would the leadership come from? How would it be funded?
I am pleased to report that this is, in fact, happening.
Continue reading →